1.
Publisher Correction: Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma
by Amaria, Rodabe N
Nature medicine, 2018-12, Vol.24 (12), p.1942-1942
2.
Author Correction: Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma
by Amaria, Rodabe N
Nature medicine, 2018-12, Vol.24 (12), p.1941-1941
3.
Are we there yet? Prolonged MAPK inhibition in BRAF.sup.V600-mutant melanoma
by Khushalani, Nikhil I
The lancet oncology, 2016-09-01, Vol.17 (9), p.1178
4.
Community experience of vemurafenib for BRAF.sup.V600 melanoma
by Hersey, Peter
The lancet oncology, 2014-04-01, Vol.15 (4), p.369
5.
Robust tumor immunity to melanoma mediated by interleukin-9-producing T cells
by Purwar, Rahul
Nature medicine, 2012-08, Vol.18 (8), p.1248-1253
6.
Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma
by Amaria, Rodabe N
Nature medicine, 2018-11, Vol.24 (11), p.1649-1654
7.
Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response
by Jiang, Peng
Nature medicine, 2018-10, Vol.24 (10), p.1550-1558
8.
Adjuvant radiotherapy versus observation alone for patients at risk of lymph-node field relapse after therapeutic lymphadenectomy for melanoma: a randomised trial
by Burmeister, Bryan H, Prof
The lancet oncology, 2012, Vol.13 (6), p.589-597
9.
Prospective identification of neoantigen-specific lymphocytes in the peripheral blood of melanoma patients
by Gros, Alena
Nature medicine, 2016-04, Vol.22 (4), p.433-438
10.
Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial
by Falchook, Gerald S, Dr
The lancet oncology, 2012, Vol.13 (8), p.782-789
11.
Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial
by Ribas, Antoni, Prof
The lancet oncology, 2015, Vol.16 (8), p.908-918
12.
Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, p...
by Dummer, Reinhard
The lancet oncology, 2018-10, Vol.19 (10), p.1315-1327
13.
Integrative molecular and clinical modeling of clinical outcomes to PD1 blockade in patients with metastatic melanoma
by Liu, David
Nature medicine, 2019-12, Vol.25 (12), p.1916-1927
14.
Association of body-mass index and outcomes in patients with metastatic melanoma treated with targeted therapy, immunotherapy, or chemotherapy: a retrospective, multicohort analysi...
by McQuade, Jennifer L
The lancet oncology, 2018-03, Vol.19 (3), p.310-322
15.
Vemurafenib in patients with BRAF(V600) mutated metastatic melanoma: An open-label, multicentre, safety study
by Larkin, James
The lancet oncology, 2014-04, Vol.15 (4), p.436-444
16.
Robust prediction of response to immune checkpoint blockade therapy in metastatic melanoma
by Auslander, Noam
Nature medicine, 2018-10, Vol.24 (10), p.1545-1549
17.
Oncogenic B-Raf.sup.V600E abrogates the AKT/B-Raf/Mps1 interaction in melanoma cells
Cancer letters, 2013-08-28, Vol.337 (1), p.125
18.
Neoadjuvant plus adjuvant dabrafenib and trametinib versus standard of care in patients with high-risk, surgically resectable melanoma: a single-centre, open-label, randomised, pha...
by Amaria, Rodabe N
The lancet oncology, 2018-02, Vol.19 (2), p.181-193
19.
Noncutaneous Melanomas: A Single-Center Analysis
by Del Prete, Valerio
Dermatology (Basel), 2016-02, Vol.232 (1), p.22-29
20.
Full-length mRNA-Seq from single-cell levels of RNA and individual circulating tumor cells
by RAMSKÖLD, Daniel
Nature biotechnology, 2012, Vol.30 (8), p.777-782
